Publications by authors named "P Donnellan"

Objective: We evaluated the accuracy of oncologists' estimates of expected survival time in recurrent ovarian cancer.

Methods: Oncologists estimated expected survival time at baseline for each patient, who were then followed up for survival time. We hypothesized that oncologists' estimates of expected survival time would be independently significant predictors of survival, unbiased (approximately equal proportions [50%] living longer versus shorter than their expected survival time), or imprecise (<30% within 0.

View Article and Find Full Text PDF

Background: Tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) inhibitor pathway with immune checkpoint blockade have shown promising outcomes in managing metastatic renal cancer. However, they increase the risk of a person developing high blood pressure and cardiovascular complications.

Case Summary: In this study, we report the case of a 73-year-old woman on axitinib and pembrolizumab for her Stage 4 renal cell carcinoma.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to assess the baseline symptom burden experienced by patients with recurrent ovarian cancer and its relationship with progression-free survival and overall survival.
  • Analysis involved 948 patients with either platinum-resistant or potentially platinum-sensitive recurrent ovarian cancer receiving advanced chemotherapy, revealing that a significant majority experienced mild to severe symptoms, including pain, fatigue, and anxiety.
  • Results showed that higher symptom burden was linked to reduced progression-free survival and overall survival, highlighting the need for effective symptom management in clinical settings and trials.
View Article and Find Full Text PDF

Apalutamide is a novel nonsteroidal androgen receptor inhibitor that has been shown to improve outcomes for patients with nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer when combined with androgen deprivation therapy. Apalutamide-induced skin rash occurred commonly in clinical trials, with 23.8-27.

View Article and Find Full Text PDF